Riverain Medical Announces New Hires and Promotions
Dayton, OH - Riverain Medical, an industry leader and innovator in computer-aided detection (CAD) and diagnostic technologies, today announced key personnel appointments to its marketing, research and sales teams.
- Kirk Mundy joins Riverain as Vice President of Marketing. Mundy comes to Riverain with over 20 years experience in the healthcare arena, specifically in the pharmaceutical and device markets. In his position Mundy will work in collaboration with Riverain teams to help synergize the company's marketing and sales functions.
- Steve Worrell joins the company as Vice President of Research. During his more than twenty-year career, Worrell has developed several new technologies and applications for CAD, most notably in the mammography market. Worrell will be responsible for the direction of all CAD applications for the early detection of lung cancer.
- Dan Clark has been appointed Eastern Zone Director of Sales; and Mike Roberts has been promoted to Western Zone Director of Sales. Both report to Kevin McBride, Vice President of Sales. Clark and Roberts will be responsible for managing and building current client relationships and overseeing new business development in their respective territories.
"We are pleased to announce these new additions to the Riverain team. Each brings great depth of experience in their respective areas of expertise," stated Sam Finkelstein, President, Riverain Medical. "We look forward to their contribution to the continued success and growth of the company."
Riverain Medical is dedicated to developing computer-aided detection (CAD) systems, medical imaging software solutions, and information services applications for the medical community. Riverain's initial products are focused on early-stage detection of lung cancer, with plans to build upon this base and develop detection systems for additional diseases and radiology devices.
Riverain's OnGuardTM Chest X-Ray CAD system is a significant technological breakthrough in the detection of early-stage lung cancer. For more information on Riverain Medical and OnGuard, please visit www.riverainmedical.com.